Zhejiang Jolly Pharmaceutical Co.,LTD (300181.SZ)
CNY 16.1
(-0.19%)
CNY 16.1
(-0.19%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 448.7 Million CNY | 34.24% |
| 2022 | 337.21 Million CNY | 49.91% |
| 2021 | 224.94 Million CNY | 104.57% |
| 2020 | 109.95 Million CNY | 275.25% |
| 2019 | 29.3 Million CNY | -6.46% |
| 2018 | 31.32 Million CNY | -39.47% |
| 2017 | 51.75 Million CNY | -11.13% |
| 2016 | 58.24 Million CNY | -27.1% |
| 2015 | 79.88 Million CNY | -19.5% |
| 2014 | 99.23 Million CNY | 43.19% |
| 2013 | 69.3 Million CNY | 24.01% |
| 2012 | 55.88 Million CNY | 21.77% |
| 2011 | 45.89 Million CNY | 34.56% |
| 2010 | 34.1 Million CNY | 32.82% |
| 2009 | 25.67 Million CNY | 238.71% |
| 2008 | 7.58 Million CNY | 64.31% |
| 2007 | 4.61 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 144.74 Million CNY | -17.96% |
| 2024 Q3 | 149.74 Million CNY | 3.46% |
| 2024 Q1 | 176.42 Million CNY | 3.32% |
| 2023 Q1 | 113.7 Million CNY | 19.45% |
| 2023 Q4 | 170.75 Million CNY | 57.72% |
| 2023 Q3 | 108.26 Million CNY | -6.21% |
| 2023 Q2 | 115.43 Million CNY | 1.52% |
| 2023 FY | 452.69 Million CNY | 34.24% |
| 2022 Q1 | 82.9 Million CNY | 36.47% |
| 2022 FY | 337.21 Million CNY | 49.91% |
| 2022 Q4 | 95.19 Million CNY | 17.21% |
| 2022 Q3 | 81.21 Million CNY | 4.25% |
| 2022 Q2 | 77.9 Million CNY | -6.03% |
| 2021 FY | 224.94 Million CNY | 104.57% |
| 2021 Q4 | 60.74 Million CNY | 4.68% |
| 2021 Q3 | 58.02 Million CNY | 11.93% |
| 2021 Q2 | 51.84 Million CNY | -4.58% |
| 2021 Q1 | 54.33 Million CNY | 49.02% |
| 2020 FY | 109.95 Million CNY | 275.25% |
| 2020 Q3 | 37.84 Million CNY | 63.14% |
| 2020 Q1 | 12.45 Million CNY | 216.82% |
| 2020 Q2 | 23.2 Million CNY | 86.33% |
| 2020 Q4 | 36.45 Million CNY | -3.68% |
| 2019 Q2 | 15.89 Million CNY | 28.72% |
| 2019 FY | 29.3 Million CNY | -6.46% |
| 2019 Q3 | 11.71 Million CNY | -26.32% |
| 2019 Q4 | -10.65 Million CNY | -190.99% |
| 2019 Q1 | 12.35 Million CNY | 503.53% |
| 2018 Q3 | -8.99 Million CNY | -128.58% |
| 2018 FY | 31.32 Million CNY | -39.47% |
| 2018 Q2 | 31.46 Million CNY | 164.13% |
| 2018 Q4 | -3.06 Million CNY | 65.97% |
| 2018 Q1 | 11.91 Million CNY | -52.88% |
| 2017 Q4 | 25.28 Million CNY | 441.49% |
| 2017 Q3 | -7.4 Million CNY | -135.11% |
| 2017 Q1 | 12.78 Million CNY | 373.58% |
| 2017 FY | 51.75 Million CNY | -11.13% |
| 2017 Q2 | 21.08 Million CNY | 64.9% |
| 2016 Q2 | 29.89 Million CNY | 26.81% |
| 2016 FY | 58.24 Million CNY | -27.1% |
| 2016 Q4 | -4.67 Million CNY | -149.48% |
| 2016 Q1 | 23.57 Million CNY | 110.42% |
| 2016 Q3 | 9.44 Million CNY | -68.39% |
| 2015 Q4 | 11.2 Million CNY | -37.14% |
| 2015 FY | 79.88 Million CNY | -19.5% |
| 2015 Q3 | 17.82 Million CNY | -39.71% |
| 2015 Q2 | 29.55 Million CNY | 38.74% |
| 2015 Q1 | 21.3 Million CNY | -30.97% |
| 2014 Q4 | 30.86 Million CNY | 18.02% |
| 2014 Q3 | 26.14 Million CNY | -7.7% |
| 2014 FY | 99.23 Million CNY | 43.19% |
| 2014 Q1 | 14.79 Million CNY | 2.6% |
| 2014 Q2 | 28.32 Million CNY | 91.46% |
| 2013 Q4 | 14.42 Million CNY | -27.58% |
| 2013 FY | 69.3 Million CNY | 24.01% |
| 2013 Q3 | 19.91 Million CNY | -12.4% |
| 2013 Q2 | 22.73 Million CNY | 85.83% |
| 2013 Q1 | 12.23 Million CNY | -5.1% |
| 2012 Q4 | 12.89 Million CNY | -17.6% |
| 2012 Q3 | 15.64 Million CNY | -13.37% |
| 2012 Q2 | 18.05 Million CNY | 94.34% |
| 2012 FY | 55.88 Million CNY | 21.77% |
| 2012 Q1 | 9.29 Million CNY | -17.57% |
| 2011 Q3 | 12.84 Million CNY | -16.27% |
| 2011 Q1 | 6.8 Million CNY | 3.79% |
| 2011 Q2 | 15.33 Million CNY | 125.3% |
| 2011 Q4 | 11.27 Million CNY | -12.22% |
| 2011 FY | 45.89 Million CNY | 34.56% |
| 2010 FY | 34.1 Million CNY | 32.82% |
| 2010 Q4 | 6.55 Million CNY | -39.1% |
| 2010 Q2 | 13.68 Million CNY | 342.01% |
| 2010 Q3 | 10.76 Million CNY | -21.3% |
| 2010 Q1 | 3.09 Million CNY | 0.0% |
| 2009 FY | 25.67 Million CNY | 238.71% |
| 2008 FY | 7.58 Million CNY | 64.31% |
| 2007 FY | 4.61 Million CNY | 0.0% |